MA54472A - Anticorps anti-périostine et leurs utilisations - Google Patents
Anticorps anti-périostine et leurs utilisationsInfo
- Publication number
- MA54472A MA54472A MA054472A MA54472A MA54472A MA 54472 A MA54472 A MA 54472A MA 054472 A MA054472 A MA 054472A MA 54472 A MA54472 A MA 54472A MA 54472 A MA54472 A MA 54472A
- Authority
- MA
- Morocco
- Prior art keywords
- periostin antibodies
- periostin
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779996P | 2018-12-14 | 2018-12-14 | |
US201962899075P | 2019-09-11 | 2019-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54472A true MA54472A (fr) | 2022-03-23 |
Family
ID=71075443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054472A MA54472A (fr) | 2018-12-14 | 2019-12-13 | Anticorps anti-périostine et leurs utilisations |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220010003A1 (fr) |
EP (1) | EP3894439A4 (fr) |
JP (2) | JP2022513228A (fr) |
KR (1) | KR20210108972A (fr) |
CN (1) | CN113631571A (fr) |
AU (1) | AU2019395887A1 (fr) |
BR (1) | BR112021010634A2 (fr) |
CA (1) | CA3120059A1 (fr) |
CL (1) | CL2021001297A1 (fr) |
CO (1) | CO2021007444A2 (fr) |
CR (1) | CR20210310A (fr) |
DO (1) | DOP2021000113A (fr) |
EC (1) | ECSP21043288A (fr) |
IL (1) | IL283890A (fr) |
JO (1) | JOP20210144A1 (fr) |
MA (1) | MA54472A (fr) |
MX (1) | MX2021007043A (fr) |
PE (1) | PE20211962A1 (fr) |
SG (1) | SG11202103849TA (fr) |
WO (1) | WO2020121059A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4028056A4 (fr) * | 2019-09-11 | 2023-10-11 | Boehringer Ingelheim IO Canada Inc. | Méthodes de traitement du cancer par l'utilisation d'inhibiteurs de l'axe pd-1 et d'anticorps anti-périostine |
KR20240038198A (ko) | 2022-09-15 | 2024-03-25 | 한남대학교 산학협력단 | 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
EP0714409A1 (fr) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Anticorps |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2007096142A2 (fr) * | 2006-02-22 | 2007-08-30 | Philogen Spa | Marqueurs de tumeurs vasculaires |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN116425875A (zh) * | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
-
2019
- 2019-12-13 AU AU2019395887A patent/AU2019395887A1/en active Pending
- 2019-12-13 SG SG11202103849TA patent/SG11202103849TA/en unknown
- 2019-12-13 MA MA054472A patent/MA54472A/fr unknown
- 2019-12-13 US US17/413,094 patent/US20220010003A1/en active Pending
- 2019-12-13 CA CA3120059A patent/CA3120059A1/fr active Pending
- 2019-12-13 WO PCT/IB2019/001307 patent/WO2020121059A1/fr unknown
- 2019-12-13 PE PE2021000873A patent/PE20211962A1/es unknown
- 2019-12-13 KR KR1020217022051A patent/KR20210108972A/ko unknown
- 2019-12-13 CR CR20210310A patent/CR20210310A/es unknown
- 2019-12-13 CN CN201980082813.0A patent/CN113631571A/zh active Pending
- 2019-12-13 JO JOP/2021/0144A patent/JOP20210144A1/ar unknown
- 2019-12-13 JP JP2021534246A patent/JP2022513228A/ja active Pending
- 2019-12-13 EP EP19897138.4A patent/EP3894439A4/fr active Pending
- 2019-12-13 BR BR112021010634A patent/BR112021010634A2/pt unknown
- 2019-12-13 MX MX2021007043A patent/MX2021007043A/es unknown
-
2021
- 2021-05-18 CL CL2021001297A patent/CL2021001297A1/es unknown
- 2021-06-08 CO CONC2021/0007444A patent/CO2021007444A2/es unknown
- 2021-06-10 IL IL283890A patent/IL283890A/en unknown
- 2021-06-11 DO DO2021000113A patent/DOP2021000113A/es unknown
- 2021-06-14 EC ECSENADI202143288A patent/ECSP21043288A/es unknown
-
2023
- 2023-07-27 JP JP2023122675A patent/JP2023139243A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20210310A (es) | 2021-11-24 |
JP2023139243A (ja) | 2023-10-03 |
SG11202103849TA (en) | 2021-05-28 |
US20220010003A1 (en) | 2022-01-13 |
BR112021010634A2 (pt) | 2021-11-16 |
CN113631571A (zh) | 2021-11-09 |
DOP2021000113A (es) | 2021-09-30 |
CA3120059A1 (fr) | 2020-06-18 |
JOP20210144A1 (ar) | 2023-01-30 |
MX2021007043A (es) | 2021-08-11 |
CO2021007444A2 (es) | 2021-09-30 |
KR20210108972A (ko) | 2021-09-03 |
IL283890A (en) | 2021-07-29 |
PE20211962A1 (es) | 2021-10-04 |
CL2021001297A1 (es) | 2022-01-07 |
EP3894439A1 (fr) | 2021-10-20 |
WO2020121059A1 (fr) | 2020-06-18 |
EP3894439A4 (fr) | 2022-11-30 |
JP2022513228A (ja) | 2022-02-07 |
ECSP21043288A (es) | 2021-09-30 |
AU2019395887A1 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA53168A (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
MA52970A (fr) | Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations | |
MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA52426A (fr) | Conjugués d'il-15 et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA52771A (fr) | Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques | |
MA52094A (fr) | Anticorps anti-il-27 et leurs utilisations |